Asymmetric modulation of a catecholamine-regulated protein in the rat brain, following quinpirole administration

Synapse

Volumn 49, Issue 4, 2003, Pages 261-269

  Gabriele, Joseph ^a   Culver, Kirsten ^a   Sharma, Sunjay ^a   Zhang, Bingjun ^a   Szechtman, Henry ^a   Mishra, Ram ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Asymmetry; CRP40; Dopamine; Molecular chaperone

Indexed keywords

BQ 24193 PROTEIN; CATECHOLAMINE; CATECHOLAMINE REGULATED PROTEIN 40; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLUCOSE REGULATED PROTEIN 78; GRP 78 PROTEIN; HALOPERIDOL; HEAT SHOCK PROTEIN 70; PROTEIN; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ASYMMETRY; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; LOCOMOTION; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEQUENCE HOMOLOGY; STEREOTYPY; VENTRAL TEGMENTUM;

ANIMALS; BLOTTING, WESTERN; BRAIN; DOPAMINE AGONISTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HSP70 HEAT-SHOCK PROTEINS; MALE; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; QUINPIROLE; RATS; RATS, LONG-EVANS;

EID: 0041766250     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10224     Document Type: Article

References (62)

1. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA. 1999. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-1589.
2. Banks KE, Gratton A. 1995. Possible involvement of medial prefrontal cortex in amphetamine-induced sensitization of mesolimbic dopamine function. Eur J Pharmacol 282:157-167.
3. Bannon MJ, Roth RH. 1983. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 35:53-68.
4. Bear MF, Connors BW, Paradiso MA. 2001. Neuroscience: exploring the brain, 2nd ed. Baltimore: Lippincott Williams & Wilkins.
5. Ben Zvi AP, Goloubinoff P. 2001. Review: mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones. J Struct Biol 135:84-93.
6. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Carlson JN, Visker KE, Keller Jr RW, Glick SD. 1996. Left and right 6-hydroxydopamine lesions of the medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral response to stress. Brain Res 711:1-9.
8. Carr DB, Sesack SR. 2000. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 20:3864-3873.
9. Chen NN, Pan WH. 2000. Regulatory effects of D2 receptors in the ventral tegmental area on the mesocorticolimbic dopaminergic pathway. J Neurochem 74:2576-2582.
10. Chiueh CC, Miyake H, Peng MT. 1993. Role of dopamine autooxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 60:251-258.
11. Culver KE, Rosenfeld JM, Szechtman H. 2000. A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats. Psychopharmacology (Berl) 151:202-210.
12. Culver K, Rosenfeld J, Szechtman H. 2002. Monoamine oxidase inhibitor-induced blockade of locomotor sensitization to quinpirole: role of striatal dopamine uptake inhibition. Neuropharmacology 43:385.
13. Deutch AY. 1992. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36:61-89.
14. Deutch AY, Clark WA, Roth RH. 1990. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 521:311-315.
15. Eilam D, Szechtman H. 1989. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161:151-157.
16. Finlay JM. 2001. Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr Bull 27:431-442.
17. Gabriele J, Rajaram M, Zhang B, Sharma S, Mishra RK. 2002. Modulation of a 40-kDa catecholamine-regulated protein following D-amphetamine treatment in discrete brain regions. Eur J Pharmacol 453:13.
18. Gariano RF, Groves PM. 1988. Burst firing induced in midbrain dopamine neurons by stimulation of the medial prefrontal and anterior cingulate cortices. Brain Res 462:194-198.
19. Garris PA, Collins LB, Jones SR, Wightman RM. 1993. Evoked extra-cellular dopamine in vivo in the medial prefrontal cortex. J Neurochem 61:637-647.
20. Grover A. 2002. Molecular biology of stress responses. Cell Stress Chaperones 7:1-5.
21. Heidbreder CA, Baumann MH. 2001. Autoregulation of dopamine synthesis in subregions of the rat nucleus accumbens. Eur J Pharmacol 411:107-113.
22. Imperato A, Tanda G, Frau R, Di Chiara G. 1988. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J Pharmacol Exp Ther 245:257-264.
23. Jackson ME, Moghaddam B. 2001. Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. J Neurosci 21:676-681.
24. Kalivas PW, Stewart J. 1991. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16:223-244.
25. King D, Finlay JM. 1997. Loss of dopamine terminals in the medial prefrontal cortex increased the ratio of DOPAC to DA in tissue of the nucleus accumbens shell: role of stress. Brain Res 767:192-200.
26. King D, Zigmond MJ, Finlay JM. 1997. Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell. Neuroscience 77:141-153.
27. 3H]quinpirole binding by monoamine oxidase inhibitors. Life Sci 71:2691-2700.
28. 3H]dopamine and [14C] acetylcholine release from nucleus caudatus slices: differences between spontaneously hypertensive rats and Wistar-Kyoto rats. Brain Res 509:266-272.
29. Maisonneuve IM, Keller RW, Glick SD. 1990. Similar effects of D-amphetamine and cocaine on extracellular dopamine levels in medial prefrontal cortex of rats. Brain Res 535:221-226.
30. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
31. Mitchell JB, Gratton A. 1992. Partial dopamine depletion of the prefrontal cortex leads to enhanced mesolimbic dopamine release elicited by repeated exposure to naturally reinforcing stimuli. J Neurosci 12:3609-3618.
32. Modi PI, Kashyap A, Nair VD, Ross GM, Fu M, Savelli JE, Marcotte ER, Barlas C, Mishra RK, 1996, Modulation of brain catecholamine absorbing proteins by dopaminergic agents. Eur J Pharmacol 299:213-220.
33. Munro LJ, Kokkinidis L, 1997. Infusion of quinpirole and muscimol into the ventral tegmental area inhibits fear-potentiated startle: implications for the role of dopamine in fear expression, Brain Res 746:231-238.
34. Nair VD, Mishra RK. 2001. Molecular cloning, localization and characterization of a 40-kDa catecholamine-regulated protein. J Neurochem 76:1142-1152.
35. Pierce RC, Kalivas PW. 1997. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25:192-216.
36. Primus RJ, Thurkauf A, Xu J, Yevich E, McInerney S, Shaw K, Tallman JF, Gallagher DW. 1997. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. J Pharmacol Exp Ther 282:1020-1027.
37. Pycock CJ, Kerwin RW, Carter CJ. 1980. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286:74-76.
38. Robinson TE, Becker JB. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis, Brain Res 396:157-198.
39. Rosenkranz JA, Grace AA. 2002. Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo, J Neurosci 22:324-337.
40. Ross GM, McCarry BE, Thakur S, Mishra RK. 1993. Identification of novel catecholamine absorbing proteins in the central nervous system. J Mol Neurosci 4:141-148.
41. Ross GM, McCarry BE, Mishra RK. 1995. Covalent affinity labeling of brain catecholamine-absorbing proteins using a high-specific-activity substituted tetrahydronaphthalene. J Neurochem 65:2783-2789.
42. Sanyal S, Van Tol HH. 1997. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. J Psychiatr Res 31:219-232.
43. Sharan N, Nair VD, Mishra RK. 2001. Modulation of a 40-kDa catecholamine regulated protein by dopamine receptor antagonists. Eur J Pharmacol 413:73-79.
44. Sharan N, Chong VZ, Nair VD, Mishra RK, Hayes RJ, Gardner EL. 2003. Cocaine treatment increases expression of a 40 kDa catecholamine-regulated protein in discrete brain regions. Synapse 47:33-44.
45. Smith Y, Bevan MD, Shink E, Bolam JP. 1998. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 86:353-387.
46. Soti C, Csermely P. 2002a. Chaperones and aging: role in neurodegeneration and in other civilizational diseases. Neurochem Int 41:383-389.
47. Soti C, Csermely P. 2002b. Chaperones come of age. Cell Stress Chaperones 7:186-190.
48. Subramaniam S, Lucki I, McGonigle P. 1992. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors. Brain Res 571:313-322.
49. Subramaniam S, Marcotte ER, Srivastava LK. 2001. Differential changes in synaptic terminal protein expression between nucleus accumbens core and shell in the amphetamine-sensitized rat. Brain Res 901:175-183.
50. Sullivan RM, Talangbayan H, Einat H, Szechtman H. 1998. Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience 83:781-789.
51. Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM. 1994a. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 48:921-928.
52. Szechtman H, Talangbayan H, Canaran G, Dai H, Eilam D. 1994b. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism. Psychopharmacology (Berl) 115:95-104.
53. Szechtman H, Eckert MJ, Tse WS, Boersma JT, Bonura CA, McClelland JZ, Culver KE, Eilam D. 2001. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci 2:4.
54. Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H. 1997. Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology (Berl) 134:193-200.
55. Szumlinski KK, Goodwill AM, Szechtman H. 2000. Locomotor sensitization to quinpirole in rats: effects of drug abstinence and sex. Psychopharmacology (Berl) 152:304-311.
56. Taber MT, Fibiger HC. 1997. Activation of the mesocortical dopamine system by feeding: lack of a selective response to stress. Neuroscience 77:295-298.
57. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ. 1998a. Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2-, and D4-like receptors. Neuroscience 83:169-176.
58. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ. 1998b. Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors. Synapse 30:227-235.
59. Weinberger DR. 1987. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669.
60. Westerink BH, Kwint HF, deVries JB. 1996. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16:2605-2611.
61. Yao JK, Reddy RD, van Kammen DP. 2001. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310.
62. Zahm DS. 1999. Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Ann NY Acad Sci 877:113-128.